There was a flurry of 340B lobbying activity at the start of 2024, including spending by the joint drugmaker-provider lobbying group, 340B Working Table.

340B Lobbying Continues Rapid Pace Including by Big Name Firms

The 340B drug discount program—and congressional activity associated with it—remained a hot topic for lobbyists in the first three months [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at